Wolverine Trading, LLC Arbutus Biopharma Corp Call Options Transaction History

Wolverine Trading, LLC

  • $97.8 Billion
  • Q1 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$1.91 - $2.85 $29,414 - $43,890
-15,400 Reduced 42.78%
20,600 $48,000
Q3 2022

Nov 14, 2022
BUY
$1.88 - $2.88 $19,364 - $29,664
10,300 Added 40.08%
36,000 $71,000
Q2 2022

Aug 15, 2022
SELL
$1.98 - $3.17 $25,344 - $40,576
-12,800 Reduced 33.25%
25,700 $69,000
Q1 2022

May 16, 2022
SELL
$2.42 - $3.98 $16,214 - $26,666
-6,700 Reduced 14.82%
38,500 $115,000
Q4 2021

Feb 14, 2022
BUY
$3.11 - $4.61 $140,572 - $208,372
45,200 New
45,200 $175,000

Others Institutions Holding ABUS

# of Institutions
129
Shares Held
82.1M
Call Options Held
4.82M
Put Options Held
546K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $585M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email